文献速递白血病造血干细胞移植与细胞治疗

Siglec-6:急性髓系白血病CAR-T治疗的新靶点

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
PubMed 文献 · Blood · 2021-01-01

该研究设计了一种以人单克隆抗体JML-1为靶向域的Siglec-6特异性CAR-T细胞。临床前模型显示,Siglec-6在AML细胞系、原代AML原始细胞及AML干细胞亚群中常见表达,CAR-T治疗可产生与Siglec-6表达相关的特异性抗白血病反应,并在免疫缺陷小鼠异种移植AML模型中诱导完全缓解;Siglec-6在正常造血干/祖细胞上检测不到,且不影响其活力与谱系分化。

要点

  • Siglec-6在AML细胞系、原代AML原始细胞及AML干细胞亚群中常见表达
  • Siglec-6 CAR-T在异种移植AML模型中诱导完全缓解
  • 正常造血干/祖细胞未检出Siglec-6,集落形成实验显示其活力与谱系分化不受影响

核心结论

  • Siglec-6 CAR-T细胞可能有效治疗AML,且或无需后续异基因造血干细胞移植。
  • 正常造血干/祖细胞不表达Siglec-6,这将其与Siglec-3(CD33)、CD123等其他AML CAR靶点区分开来,值得临床研究。

研究设计与样本

  • 临床前研究:设计以人单克隆抗体JML-1来源靶向域的Siglec-6特异性CAR,在AML细胞系、原代AML原始细胞、免疫缺陷小鼠异种移植模型(NSG/U937)及集落形成实验中评价。
  • 同时检测慢性淋巴细胞白血病(CLL)转化B细胞上的Siglec-6表达及体外抗CLL反应。

主要发现

  • Siglec-6在AML细胞系和原代AML原始细胞(包括AML干细胞亚群)中常见表达。
  • Siglec-6 CAR-T细胞的抗白血病反应与Siglec-6表达相关,并在NSG/U937异种移植AML模型中诱导完全缓解。
  • CLL转化B细胞表達Siglec-6,Siglec-6 CAR-T在体外显示特异性抗CLL反应。
  • 正常造血干/祖细胞未检出Siglec-6,集落形成实验中其活力与谱系分化不受影响。
  • 成熟正常造血细胞中,部分记忆(及初始)B细胞和嗜碱性粒细胞检出Siglec-6,提示可能存在有限的on-target/off-tumor反应。

临床怎么用

  • 临床前数据支持对Siglec-6 CAR-T细胞疗法开展临床研究,用于AML治疗。
  • 因正常造血干/祖细胞不表达Siglec-6,该疗法或可免除后续异基因造血干细胞移植。
  • 需关注部分记忆/初始B细胞和嗜碱性粒细胞表达Siglec-6带来的on-target/off-tumor风险。

局限性

  • 证据来自临床前模型(细胞系、原代细胞、NSG/U937异种移植及体外实验),尚需临床研究验证。
  • 成熟正常造血细胞中部分B细胞和嗜碱性粒细胞检出Siglec-6,提示潜在on-target/off-tumor反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is an attractive entity for the development of chimeric antigen receptor (CAR) T-cell immunotherapy because AML blasts are susceptible to T-cell-mediated elimination. Here, we introduce sialic acid-binding immunoglobulin-like lectin 6 (Siglec-6) as a novel target for CAR T cells in AML. We designed a Siglec-6-specific CAR with a targeting domain derived from the human monoclonal antibody JML-1. We found that Siglec-6 is commonly expressed on AML cell lines and primary AML blasts, including the subpopulation of AML stem cells. Treatment with Siglec-6 CAR T cells confers specific antileukemia reactivity that correlates with Siglec-6 expression in preclinical models, including induction of complete remission in a xenograft AML model in immunodeficient mice (NSG/U937). In addition, we confirmed Siglec-6 expression on transformed B cells in chronic lymphocytic leukemia (CLL), and specific anti-CLL reactivity of Siglec-6 CAR T cells in vitro. Of particular interest, we found that Siglec-6 is not detectable on normal hematopoietic stem and progenitor cells (HSPCs) and that treatment with Siglec-6 CAR T cells does not affect their viability and lineage differentiation in colony-formation assays. These data suggest that Siglec-6 CAR T-cell therapy may be used to effectively treat AML without the need for subsequent allogeneic hematopoietic stem cell transplantation. In mature normal hematopoietic cells, we detected Siglec-6 in a proportion of memory (and naïve) B cells and basophilic granulocytes, suggesting the potential for limited on-target/off-tumor reactivity. The lack of expression of Siglec-6 on normal HSPCs is a key to differentiating it from other Siglec family members (eg, Siglec-3 [CD33]) and other CAR target antigens (eg, CD123) that are under investigation in AML, and it warrants the clinical investigation of Siglec-6 CAR T-cell therapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Jetani H, Navarro-Bailón A, Maucher M, et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood. 2021. PMID: 34289026. doi:10.1182/blood.2020009192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。